A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)

Merck Sharp & Dohme LLC451 enrolled

Overview

This is an observational, non-comparative, multicenter, open-label study. Participants will be treated with Raltegravir according to standard clinical practice, and monitored over a total period of 96 weeks. In an extension to the study (Amendment 1), a new cohort of aging participants (≥ 50 years) will be recruited and monitored over a total period of 48 weeks. Participants who stop taking Raltegravir before the end of the 96-week period or 48-week period, respectively, will be followed up for 3 months after discontinuing the drug. The primary objective is to determine the proportion of participants with a human immunodeficiency virus (HIV)-1 viral load \< 50 copies/mL after 48 weeks of treatment with Raltegravir.

Study Type

OBSERVATIONAL

Enrollment

451

Conditions

HIV-1 Infection

Interventions

RaltegravirDRUG

Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 48 or 144 weeks

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria The prospective participant must meet, at least, all of the criteria below to be eligible for study participation. The participant: * Is a minimum age of 18 years (adults) or 50 years (aging participants); * Is male or female; * Has confirmed infection with HIV-1 (positive HIV test according to appropriate standard practice); * Has commenced antiretroviral treatment with Raltegravir according to the recommendations made in the Summary of Product Characteristics at the time of enrollment on the study, or a maximum 6 months prior to enrollment on the study; * Has any cluster of differentiation (CD4) cell (specialized white blood cell) count upon enrollment on the study. Exclusion criteria If the prospective participant meets any of the criteria below (among others determined by the study staff) they will NOT be eligible for study participation. The participant: * For which Raltegravir, or its ingredients, are contraindicated; * Has intolerance to Raltegravir, or its ingredients; * If female, is pregnant, breastfeeding, or is planning a pregnancy or egg donation during the study.

Outcomes

Primary Outcomes

Percentage of Participants With an HIV-1 Viral Load <50 Copies/mL After 48 Weeks of Raltegravir Treatment

The percentage of participants with an HIV-1 viral load \<50 copies/mL of HIV-1 RNA after 48 weeks of raltegravir treatment was determined.

Time frame: Baseline and 48 weeks

Percentage of Aging Participants With an HIV-1 Viral Load <50 Copies/mL After 48 Weeks of Raltegravir Treatment

The percentage of aging participants (\>=50 years old at initiation of raltegravir treatment) with an HIV-1 viral load \<50 copies/mL of HIV-1 RNA after 48 weeks of raltegravir treatment was determined.

Time frame: Baseline and 48 weeks

Secondary Outcomes

Percentage of Participants With an HIV-1 Viral Load <50 Copies/mL After 96 Weeks of Raltegravir Treatment

The percentage of participants with an HIV-1 viral load \<50 copies/mL of HIV-1 RNA after 96 weeks of raltegravir treatment was determined.

Time frame: Baseline and 96 weeks

HIV-1 Viral Load After 96 Weeks of Raltegravir Treatment

The HIV-1 viral load (log10 copies/mL of HIV-1 RNA) was determined at Baseline and after 96 weeks of raltegravir treatment.

Time frame: Baseline and 96 weeks

Change From Baseline in CD4+ T-cell Counts After 96 Weeks of Raltegravir Treatment

Mean CD4+ T-cell counts were determined at baseline and after 96 weeks of raltegravir treatment. A positive change from baseline indicates an increase in CD4+ T-cell count.

Time frame: Baseline and 96 weeks

HIV-1 Viral Load in Aging Participants After 48 Weeks of Raltegravir Treatment

The HIV-1 viral load (log10 copies/mL of HIV-1 RNA) was determined in aging participants (\>=50 years old at initiation of raltegravir treatment) at Baseline and after 48 weeks of raltegravir treatment.

Time frame: Baseline and 48 weeks

Change From Baseline in CD4+ T-cell Counts in Aging Participants After 48 Weeks of Raltegravir Treatment

Mean CD4+ T-cell counts were determined in aging participants (\>=50 years old at initiation of raltegravir treatment) at baseline and after 48 weeks of raltegravir treatment was determined. A positive change from baseline indicates an increase in CD4+ T-cell count.

Time frame: Baseline and 48 weeks

Change From Baseline in Mean Framingham Risk Score for the 10-Year Cardiovascular Risk in Aging Participants After 48 Weeks of Raltegravir Treatment

Mean Framingham Risk for 10-year cardiovascular risk was determined in aging participants (\>=50 years old at initiation of raltegravir treatment). Points were allotted for each of following 8 risk factors : sex, age, systolic blood pressure, treatment for hypertension, smoking, diabetes, total cholesterol, and high-density lipoprotein. The sum of the points for each participant was assigned a percent 10-year cardiovascular risk on a lookup table, and could range from 0% to 100%. The mean Framingham Risk for 10-year cardiovascular risk was then calculated for the analysis population. The change from baseline was calculated as Baseline minus Week 48; a positive change indicates reduced risk. This Outcome Measure was added with Amendment 1 and applies only to aging participants.

Time frame: Baseline and 48 weeks

Change From Baseline in Mean D:A:D Risk Score for the 5-Year Cardiovascular Risk in Aging Participants After 48 Weeks of Raltegravir Treatment

Mean Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Risk Score for 5-year cardiovascular risk was determined in aging participants (\>=50 years old at initiation of raltegravir treatment) at Baseline and after 48 weeks of raltegravir treatment. The score included the following 8 risk factors: sex, age, systolic blood pressure, family cardiovascular disease history, current smoking, previous cigarette smoker, diabetes, total cholesterol, high-density lipoprotein, currently on indinavir, currently on lopinavir, currently on abacavir, duration and current use of indinavir and duration and current use of lopinavir. The D:A:D Risk Score is interpreted as low: \<1%; moderate: 1-5%; high: 5-10%; and very high: \>10%. The change from baseline was calculated as Week 48 minus Baseline; a positive change indicates increased risk. This Outcome Measure was added with Amendment 1 and applies only to aging participants.

Time frame: Baseline and 48 weeks

Percentage of Aging Participants With Concomitant Diseases at Baseline

The percentage of aging participants with Baseline comorbidities was reported. This Outcome Measure was added with Amendment 1 and applies only to aging participants.

Time frame: Baseline

Percentage of Aging Participants Taking Concomitant Medications at Baseline

The percentage of aging participants taking concomitant medication in addition to their other antiretroviral therapy was reported. This Outcome Measure was added with Amendment 1 and applies only to aging participants.

Time frame: Baseline